



## Company Overview

- Biopharmaceutical company focused on the treatment of mental health through natural drug discovery and clinical research
- Listed on the [Canadian Securities Exchange \(ABRT\)](#) and [Frankfurt Stock Exchange \(VB50\)](#)
- Extensive research and development programmes to deliver IP protected, natural drugs with a history of safety and efficacy
- Treating patients with urgent and unmet mental health needs, with access to huge and growing markets in the UK and US markets

## Financing Overview (see Term Sheet for full detail)

- Current shares outstanding: 67,280,035
  - Directors, Insiders and Management Ownership: 52,910,178 (79%)
- Tranche 1
  - Unit Price: CAD\$ 0.08; Unit = Common Share and Half-Warrant (whole warrant at CAD\$ 0.12)
- Total raise: CAD\$ 3,000,000

## Team

- A [top-tier team](#) that has successfully brought 200+ drugs to market
- A wealth of knowledge and experience across commercial market access, regulatory strategy, clinical trials, drug manufacturing and venture capital

## Locations

### *Vancouver, Canada*

- Health Canada licensed R&D and manufacturing facility
- Special Access Programme for distribution and sale of KRN API

### *Porto, Portugal*

- GLP Approved Pre-Clinical programme, including analytical and animal toxicological facility
- Infarmed scheduled substance licence

### *Melbourne, Australia*

- In-human, pharmacokinetic studies with iNGENU CRO
- 43.5% rebate from Australian Government on almost all costs

### *Manchester, United Kingdom*

- Real World Evidence, Phase 2b studies
- Leading partnerships: University of Manchester, Christie Hospital (largest oncology centre in Europe), National Cancer Research Institute
- ~250 patients suffering from cancer-related distress

## **Drug Discovery**

### *First Drug Target: KRN-101*

- A natural, psilocybin based medicine derived from mycelium extracts
- Unique asset with extensive opportunities for market exclusivity (~ 10 year protection) and speed to commercialization

*Full International Patent (~ 25 year protection) on manufacturing processes, expected award in Q1 2023*

- Consistent and scalable manufacturing of Albert Labs' drug development pipeline
- Cost effective production: 10 days to produce 1,000 (25mg) doses of KRN-101, with an estimated market value of CAD\$ 1.8 million

*Research and development on additional protected drug assets, ready for pre-clinical studies in 2023*

## **Clinical Delivery**

### *First Target Indication: Cancer-related distress*

- Extensive background of research supporting efficacy
  - *Johns Hopkins University, 2016*: 51 patients - one 25mg dose of psilocybin - 83% of participants showing statistically significant reduction after 6 months
- Highly unmet patient need, with significantly reduced regulatory risk
- Accelerates access to further depression and anxiety related indications

### *Real World Evidence Trial*

- Accelerated market approval and uptake of treatment
- Provision and future licensing of KRN-101 and the Albert Labs Psychotherapy Care Programme
- In partnership with the University of Manchester and Christie Hospital (20,000 new target patients / year)
- Expansion across the UK (50-100,000 new target patients / year, as well as immediate addressable market of 1 million patients)

### *Reimbursement and Early Revenue Strategy*

- Operating clinical and payor infrastructure that is unique to the UK - management team with vast experience of operating through mechanisms
- Access to early revenues through NHS Hospital Trusts and treatment delivery as an Unlicensed Special

### *Pharmacokinetic (PK) study*

- Deal agreed with iGENU CRO
- First patient dosed: Q2 2023
- Completion, including all clinical outputs: Q3 2023
- KRN-101 available for late-stage clinical trials and licensing
  - Ready for MHRA (UK) Real World Evidence Clinical Trial Application
  - Access to the FDA (USA) through an IND submission (planned for Q4 2023)

### **Timelines**

Q4 2022: Pre-Clinical (analytical and toxicology study) Completion:

Q2 2023: PK study Initiation

Q3 2023: PK study Completion, including collection of all clinical data; FDA (USA) pre-IND meeting and market access planning

Q4 2023: MHRA (UK) Real World Evidence Clinical Trial Application; FDA (USA) IND submission

## Additional Resources

*Website:*

<https://albertlabs.com/>

*Latest Press:*

[Letter Of Intent \(LOI\) For First-In-Human Studies With INGENŪ CRO \(17 November 2022\)](#)

[Corporate Update \(25 November 2022\)](#)

[New International PCT Patent Application for scalable API manufacturing \(20th October 2022\)](#)

*Watch:*

[Investing in Albert Labs with Kingsley Wilson of Chrystal Capital](#)

[Introduction to Mike Thompson MBE](#)

[Introduction to Professor Sara Tai](#)

*Read:*

Johns Hopkins University, 2016: [Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomised double-blind trial.](#)

Press release: New York University, 2016: [Single Dose of Hallucinogenic Drug Psilocybin Relieves Anxiety & Depression in Patients with Advanced Cancer](#)